Why the study?
Does empagliflozin improve clinical outcomes in patients with acute decompensated heart failure?
Population
Patients with acute decompensated heart failure
Comparison
Empagliflozin vs placebo
Design
Randomized, double-blind, placebo-controlled, multicentre pilot study
Follow-up
60 days
Authors
Loading...
Empagliflozin improves 60-day HF outcomes during acute hospitalization; extends SGLT2i evidence to decompensated patients despite neutral symptom effects.
Does empagliflozin improve clinical outcomes in patients with acute decompensated heart failure?
In patients with acute decompensated heart failure, empagliflozin safely increases urinary output and reduces a 60-day composite of worsening HF, rehospitalization, or death, despite no significant effect on dyspnea or NT-proBNP.
Damman et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: